Clinical trial
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients…
NCT01915303 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT01915303 |
|---|---|
| Title | Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease |
| Official title | A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cushings Disease |
| Intervention type | Drug |
| Interventions | Pasireotide with or without cabergoline |
| Enrollment | 68 |
| Start date | Mar 6, 2014 |
| Primary completion | Sep 5, 2016 |
| Completion | Sep 4, 2019 |
| First posted | Aug 2, 2013 |
| Last update posted | Sep 18, 2020 |
| Countries | Argentina, Belgium, Brazil, Colombia, France, Germany, Greece, Hungary, India, Italy, Malaysia, Mexico and 4 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: